Key result
Clopidogrel, but not aspirin, prevented alveolar bone loss, and both drugs significantly decreased CXCL4 expression (P<0.05) and myeloperoxidase activity in a rat model of periodontal disease.
Why the study?
Do antiplatelet drugs (aspirin or clopidogrel) reduce the immunoinflammatory response and bone loss in a rat model of periodontal disease?
RCT (n=60)
randomly assigned
Do antiplatelet drugs (aspirin or clopidogrel) reduce the immunoinflammatory response and bone loss in a rat model of periodontal disease?
p-value: p=<0.05
In a rat model of periodontal disease, clopidogrel but not aspirin prevented alveolar bone loss, though both reduced inflammatory markers.
Hypothesis-generating for clopidogrel in periodontal bone loss; leaves open human translation and clinical relevance.
BACKGROUND AND OBJECTIVE: After activation, platelets express mediators that modulate inflammation. We hypothesized that drug-induced platelet inactivation may interfere in the inflammatory process in experimental periodontal disease by suppressing the release of biological mediators to the injury site. MATERIAL AND METHODS: To evaluate the effects of antiplatelet drugs on experimental periodontal disease, 60 rats were randomly assigned to six groups (n = 10) and ligatures were placed around lower first molars in three groups. The other three groups were not subjected to the induction of periodontal disease and were used as negative controls. During the experimental period, animals were given aspirin (30 mg/kg) or clopidogrel (75 mg/kg) intragastrically once daily for 3 d. On day 3, they were killed and gingival tissue were used to evaluate myeloperoxidase activity and the expression of the chemokine CXCL4. Hemi-mandibles were used for microscopic evaluation. RESULTS: Clopidogrel significantly reduced the inflammatory infiltrate and increased the amount of collagen fibers. Histometric analysis showed that clopidogrel impaired alveolar bone loss. Expression of CXCL4 was significantly increased (p < 0.001) in rats subjected to periodontal disease. Systemic administration of aspirin and clopidogrel induced a significant decrease ( p < 0.05) in the expression of CXCL4. Treatment with antiplatelet drugs resulted in a significant reduction of myeloperoxidase activity when compared to saline-treated animals with periodontal disease. CONCLUSION: Clopidogrel but not aspirin showed the ability of preventing bone loss in experimental periodontitis.
No takes yet. Share an insight, caveat, or question.
Coimbra et al. (2013) conducted an RCT in experimental periodontal disease (n=60). Aspirin or clopidogrel vs. saline-treated animals with periodontal disease and negative controls was evaluated on alveolar bone loss, inflammatory infiltrate, myeloperoxidase activity, and CXCL4 expression (p=<0.05). Clopidogrel, but not aspirin, prevented alveolar bone loss, and both drugs significantly decreased CXCL4 expression (P<0.05) and myeloperoxidase activity in a rat model of periodontal disease.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: